Holen Sie sich die Stockscreener-App
17.56
7.29%
-1.38
Vorhandelsmarkt:
18.00
0.44
+2.51%
Schlusskurs vom Vortag:
$18.94
Offen:
$18.58
24-Stunden-Volumen:
103.66K
Relative Volume:
1.18
Marktkapitalisierung:
$587.09M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-3.4937
EPS:
-5.0262
Netto-Cashflow:
-
1W Leistung:
-3.46%
1M Leistung:
-24.34%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$17.56
$18.81
1-Wochen-Bereich:
$17.56
$19.67
52-Wochen-Spanne:
$17.56
$30.56
Spyglass Pharma Inc Stock (SGP) Company Profile
Firmenname
Spyglass Pharma Inc
Sektor
Branche
Telefon
949-284-6904
Adresse
27081 ALISO CREEK ROAD, ALISO VIEJO
Compare SGP vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SGP
Spyglass Pharma Inc
|
17.56 | 633.23M | 0 | 0 | 0 | -5.0262 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spyglass Pharma Inc Stock (SGP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-03-03 | Eingeleitet | Citigroup | Buy |
| 2026-03-03 | Eingeleitet | Jefferies | Buy |
| 2026-03-03 | Eingeleitet | Leerink Partners | Outperform |
| 2026-03-03 | Eingeleitet | Stifel | Buy |
Spyglass Pharma Inc Aktie (SGP) Neueste Nachrichten
SpyGlass Taps Shannon Treviño as General Counsel - Orange County Business Journal
SpyGlass Pharma appoints Shannon Treviño as general counsel to support Phase 3 trials and commercialization plans. - Pluang
SpyGlass Pharma, Inc. Announces Appointment of Shannon Treviño to General Counsel - marketscreener.com
SpyGlass Pharma appoints Shannon Treviño as general counsel - Investing.com
SpyGlass Pharma appoints Shannon Treviño as general counsel By Investing.com - Investing.com Canada
SpyGlass Pharma Appoints Shannon Treviño as General Counsel - GlobeNewswire
Spyglass Pharma (SGP) Earnings Date and Reports 2026 $SGP - MarketBeat
Spyglass Pharma (SGP) Stock Chart and Price History 2026 $SGP - MarketBeat
SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing - VisionMonday.com
SpyGlass Pharma appoints Mike Pinder as VP of marketing By Investing.com - Investing.com South Africa
SpyGlass Pharma appoints Mike Pinder as VP of marketing - Investing.com
Drop-free glaucoma BIM-IOL system taps veteran marketer - Stock Titan
SGP Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue ChallengesProfit Announcement - newsline.com
SpyGlass Pharma to Participate in Upcoming Investor Conferences - Sahm
SpyGlass Pharma: New add-on CPT code supports BIM-IOL System - Eyes On Eyecare
SpyGlass Secures Billing Code for IOL Platform - Orange County Business Journal
Spyglass Pharma IncBIM-Iol System Phase 3 Trial Enrollment Expected To Complete In 2027 - TradingView
SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System - GlobeNewswire
SpyGlass Pharma (SGP) Q1 2026 Earnings Miss by Significant: Key TakeawaysBuyback Authorization - newser.com
SpyGlass Pharma posts Q1 loss as Phase 3 trials advance By Investing.com - Investing.com South Africa
SpyGlass Pharma posts Q1 loss as Phase 3 trials advance - Investing.com India
SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates - Sahm
Number of shareholders of SpyGlass Pharma, Inc. – NASDAQ:SGP - TradingView
SpyGlass Pharma (SGP) boosts cash to $251M after IPO while losses widen - Stock Titan
SpyGlass Pharma (SGP) boosts cash with IPO and reports strong BIM-IOL glaucoma data - Stock Titan
SpyGlass Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Spyglass Pharma (SGP) Institutional Ownership 2026 $SGP - MarketBeat
Eye implant ended IOP-lowering drops for 98% in trial - Stock Titan
SGP SpyGlass Pharma reports solid late-stage trial progress, lays out aggressive commercial expansion plans for 2025.Stock Community Signals - newser.com
What fair value gap SpyGlass Pharma (SGP)? (Buying Pressure) 2026-05-01Inside Day Breakout - newsline.com
SGP Ownership | SPYGLASS PHARMA INC (NASDAQ:SGP) - ChartMill
Eye care firm SpyGlass Pharma soars 65% in trading debut - MSN
SGP Technical Analysis | Trend, Signals & Chart Patterns | SPYGLASS PHARMA INC (NASDAQ:SGP) - ChartMill
All News for SGP : SpyGlass Pharma, Inc. - Zacks Investment Research
Dividend HistorySpyGlass Pharma, Inc. (SGP) - Zacks Investment Research
Is SpyGlass Pharma (SGP) Stock Good for Long Term | Price at $22.30, Down 0.71%Earnings Miss Risk - newsline.com
SpyGlass Pharma, Inc.: Fundamental Analysis and Financial Ratings | SGP | US85220G1094 - marketscreener.com
SGP: SpyGlass Pharma, Inc.Insider Transations - Zacks Investment Research
SpyGlass Pharma, Inc. (SGP) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
SpyGlass Pharma Reports Fourth Quarter and Full-Year 2025 Results - VisionMonday.com
SpyGlass Pharma, Inc. (SGP) stock price, news, quote and history - Yahoo Finance UK
Finanzdaten der Spyglass Pharma Inc-Aktie (SGP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Spyglass Pharma Inc-Aktie (SGP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Behbahani Ali | Director |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Florence Anthony A. Jr. | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| BASKETT FOREST | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| New Enterprise Associates 17, | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Yang Rick | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Makhzoumi Mohamad | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| SANDELL SCOTT D | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Chang Carmen | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Walker Paul Edward | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Mathers Edward T | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):